Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic D

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. FDX
5. IBM
6. MU
7. META
8. USO
9. NVDA
10. BLZE

Go back to Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic D
(NASDAQ: ARQT) Delayed: 26.27 -0.39 (1.46%)
Previous Close $26.66    52 Week High $ 
Open $26.56    52 Week Low $ 
Day High $27.17    P/E N/A 
Day Low $26.18    EPS $ 
Volume 1,641,963       

(NASDAQ: ARQT) Delayed: 26.27 -0.39 (1.46%)
Previous Close $26.66    52 Week High $ 
Open $26.56    52 Week Low $ 
Day High $27.17    P/E N/A 
Day Low $26.18    EPS $ 
Volume 1,641,963